The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Going further than Lipinski's rule in drug design
Abstract
INTRODUCTION: Lipinski's 1997 publication of the 'Rule of 5' (Ro5) was one of the most influential recent medicinal chemistry publications. In the almost 15 years since the publication of the original Ro5 paper, multiple groups have refined and expanded on the Ro5 and proposed additional heuristics to guide medicinal chemistry programs. While many variations on the Ro5 have been proposed, the majority of these remain close to the original guidelines proposed by Lipinski et al. AREAS COVERED: This review provides an overview of heuristic methods for the design of drug-like molecules. The article also provides the reader with suggestions on future directions for the field. EXPERT OPINION: While Lipinski's publication of the Ro5 and subsequent work by other authors has made medicinal chemists more aware of the relationships between physical properties and ADMET, it has hardly been a panacea. Pharmaceutical productivity continues to lag, and the industry is exploring new models to improve its output. If we are to progress, we need to move beyond simple models based on lipophilicity and gain a deeper understanding of molecular interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199
Angewandte Chemie International Edition
(2006) · Angewandte Chemie International Edition · doi:10.1002/(issn)1521-3773 · Cited by 5,242
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Ghose, A. K., Viswanadhan, V. N., & Wendoloski, J. J. (1999) · Journal of Combinatorial Chemistry · doi:10.1021/cc9800071 · Cited by 3,068
The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates
Roughley, S. D., & Jordan, A. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200187y · Cited by 2,725
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Prediction of Drug Absorption Using Multivariate Statistics
Egan, W. J., Merz, & Baldwin, J. J. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000292e · Cited by 1,970
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020
Walters, W. P., Stahl, M. T., & Murcko, M. A. (1998) · Drug Discovery Today · doi:10.1016/s1359-6446(97)01163-x · Cited by 991
Self-citationGeneration of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Feher, M., & Schmidt, J. M. (2003) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci0200467 · Cited by 927
Ritchie, T. J., & Macdonald, S. J. F. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.07.014 · Cited by 901
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
The Design of Leadlike Combinatorial Libraries
Teague, S. J., Davis, A. M., Leeson, P. D., & Oprea, T. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19991216)38:24<3743::aid-anie3743>3.0.co;2-u · Cited by 870
Is There a Difference between Leads and Drugs? A Historical Perspective
Oprea, T. I., Davis, A. M., Teague, S. J., & Leeson, P. D. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010366a · Cited by 769
Structure−Brain Exposure Relationships
Hitchcock, S. A., & Pennington, L. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060642i · Cited by 698
Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Property distribution of drug-related chemical databases*
Oprea, T. I. (2000) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008130001697 · Cited by 628
Clark, D. E. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js9804011 · Cited by 627
Recent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
Pursuing the leadlikeness concept in pharmaceutical research
Hann, M. M., & Oprea, T. I. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.003 · Cited by 515
Can We Learn To Distinguish between “Drug-like” and “Nondrug-like” Molecules?
Ajay, Walters, W. P., & Murcko, M. A. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970666c · Cited by 484
Self-citationSneader, W. (2005) · Wiley eBooks · doi:10.1002/0470015535 · Cited by 427
A Scoring Scheme for Discriminating between Drugs and Nondrugs
Sadowski, J., & Kubinyi, H. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9706776 · Cited by 392
Using the Golden Triangle to optimize clearance and oral absorption
Johnson, T. W., Dress, K. R., & Edwards, M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.045 · Cited by 392
What Do Medicinal Chemists Actually Make? A 50-Year Retrospective
Walters, W. P., Green, J., Weiss, J. R., & Murcko, M. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200504p · Cited by 387
Self-citationReactive compounds and in vitro false positives in HTS
Rishton, G. M. (1997) · Drug Discovery Today · doi:10.1016/s1359-6446(97)01083-0 · Cited by 351
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic
Bird, G. H., Madani, N., Perry, A. F., Princiotto, A. M., Supko, J. G., He, X., Gavathiotis, E., Sodroski, J. G., & Walensky, L. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002713107 · Cited by 347
Clemons, P. A., Bodycombe, N. E., Carrinski, H. A., Wilson, J. A., Shamji, A. F., Wagner, B. K., Koehler, A. N., & Schreiber, S. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012741107 · Cited by 346
Time-Related Differences in the Physical Property Profiles of Oral Drugs
Leeson, P. D., & Davis, A. M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049717d · Cited by 326
Waring, M. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.109 · Cited by 326
Sneader, W. (2005) · Cited by 302
Feng, Y., Mitchison, T. J., Bender, A., Young, D. W., & Tallarico, J. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2876 · Cited by 279
Ursu, O., Rayan, A., Goldblum, A., & Oprea, T. I. (2011) · WIREs Computational Molecular Science · doi:10.1002/wcms.52 · Cited by 276 · cited 1×
“[31] that provides a comprehensive overview of the field.”
BackgroundFragment-Based Drug Design: How Big Is Too Big?
Hajduk, P. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060511h · Cited by 265
Drugs, leads, and drug-likeness: an analysis of some recently launched drugs
Proudfoot, J. R. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00244-5 · Cited by 252
Computational toxicology in drug development
Muster, W., Breidenbach, A., Fischer, H., Kirchner, S., Müller, L., & Pähler, A. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.007 · Cited by 215
Perola, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100118x · Cited by 188
Hou, T., Wang, J., Zhang, W., & Xu, X. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci6003515 · Cited by 178
Identification of Biological Activity Profiles Using Substructural Analysis and Genetic Algorithms
Gillet, V. J., Willett, P., & Bradshaw, J. (1998) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci970431+ · Cited by 176
Biopharmaceutical drug targeting to the brain
Pardridge, W. M. (2010) · Journal of Drug Targeting · doi:10.3109/10611860903548354 · Cited by 173
Current strategies for diversity-oriented synthesis
Dandapani, S., & Marcaurelle, L. A. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.018 · Cited by 170
Molecular complexity and fragment-based drug discovery: ten years on
Leach, A. R., & Hann, M. M. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.008 · Cited by 169
Influence of Molecular Flexibility and Polar Surface Area Metrics on Oral Bioavailability in the Rat
Lu, J. J., Crimin, K., Goodwin, J. T., Crivori, P., Orrenius, C., Xing, L., Tandler, P. J., Vidmar, T. J., Amore, B. M., Wilson, A. G. E., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306529 · Cited by 169
Physicochemical drug properties associated within vivotoxicological outcomes: a review
Price, D. A., Blagg, J., Jones, L. H., Greene, N., & Wager, T. T. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903042318 · Cited by 167
Drug prototypes and their exploitation
(1997) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(97)84366-8 · Cited by 147
Discriminating between Drugs and Nondrugs by Prediction of Activity Spectra for Substances (PASS)
Anzali, S., Barnickel, G., Cezanne, B., Krug, M., Filimonov, D. A., & Poroikov, V. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0010670 · Cited by 146
‘Metabolite-likeness’ as a criterion in the design and selection of pharmaceutical drug libraries
Dobson, P. D., Patel, Y., & Kell, D. B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.011 · Cited by 141
Descriptors, Physical Properties, and Drug-Likeness
Brüstle, M., Beck, B., Schindler, T., King, W., Mitchell, T. J., & Clark, T. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011027b · Cited by 121
Drug discovery in the next decade: innovation needed ASAP
Bennani, Y. L. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.004 · Cited by 120
Molecular properties that influence oral drug-like behavior.
Lajiness, M. S., Vieth, M., & Erickson, J. A. (2004) · PubMed · Cited by 102
Distinct Biological Network Properties between the Targets of Natural Products and Disease Genes
Dančík, V., Seiler, K. P., Young, D. W., Schreiber, S. L., & Clemons, P. A. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102798t · Cited by 88
Impact of ion class and time on oral drug molecular properties
Leeson, P. D., St-Gallay, S. A., & Wenlock, M. C. (2010) · MedChemComm · doi:10.1039/c0md00157k · Cited by 87
Brain drug targeting: a computational approach for overcoming blood–brain barrier
Mehdipour, A. R., & Hamidi, M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.07.009 · Cited by 78
Gradual in Silico Filtering for Druglike Substances
Schneider, N., Jäckels, C., Andrés, C., & Hutter, M. C. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci700351y · Cited by 61
Methods for the synthesis of macrocycle libraries for drug discovery
Terrett, N. K. (2010) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2010.06.002 · Cited by 61
Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules
Luker, T. J., Alcaraz, L., Chohan, K. K., Blomberg, N., Brown, D. S., Butlin, R. J., Elebring, T., Griffin, A. M., Guile, S. D., St-Gallay, S. A., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.07.074 · Cited by 60
Assessment of Methods To Define the Applicability Domain of Structural Alert Models
Ellison, C. M., Sherhod, R., Cronin, M., Enoch, S. J., Madden, J. C., & Judson, P. N. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci1000967 · Cited by 58
Comparing the chemical spaces of metabolites and available chemicals: models of metabolite-likeness
Gupta, S. V., & Aires‐de‐Sousa, J. (2007) · Molecular Diversity · doi:10.1007/s11030-006-9054-0 · Cited by 55
Li, Q., Bender, A., Pei, J., & Lai, L. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci700107y · Cited by 49
Fischer, H., Atzpodien, E.-A., Csató, M., Doessegger, L., Lenz, B. F., Schmitt, G., & Singer, T. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201082a · Cited by 45
In silicotoxicology models and databases as FDA Critical Path Initiative toolkits
Valerio, L. G. (2011) · Human Genomics · doi:10.1186/1479-7364-5-3-200 · Cited by 44
Drug prototypes and their exploitation
Timmerman, H. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)90638-6 · Cited by 35
Murcia‐Soler, M., Pérez‐Giménez, F., Garcı́a-March, F. J., Salabert-Salvador, M. T., Dı́az-Villanueva, W., & Castro-Bleda, M. J. (2003) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci0302862 · Cited by 31
Predicting Oral Druglikeness by Iterative Stochastic Elimination
Rayan, A., Marcus, D., & Goldblum, A. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci9004354 · Cited by 29
Lead optimization in the nondrug-like space
Zhao, H. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.12.002 · Cited by 27
Can ‘Bacterial-Metabolite-Likeness' Model Improve Odds of ‘in Silico' Antibiotic Discovery?
Cherkasov, A. R. (2006) · Journal of Chemical Information and Modeling · doi:10.1021/ci050480j · Cited by 24
Separating Drugs from Nondrugs: A Statistical Approach Using Atom Pair Distributions
Hutter, M. C. (2006) · Journal of Chemical Information and Modeling · doi:10.1021/ci600329u · Cited by 22
In Silico Models to Predict Brain Uptake
Abraham, M. H., & Hersey, A. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00146-2 · Cited by 12
Cited by
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., & Kruger, H. G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113705 · Cited by 625
The application of in silico drug-likeness predictions in pharmaceutical research
Tian, S., Wang, J., Li, Y., Li, D., Xu, L., & Hou, T. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.009 · Cited by 498
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Churcher, I. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01272 · Cited by 491
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
Metadata
- Authors
- Walters, W. P.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2012-01-13
- Volume
- 7
- Issue
- 2
- Pages
- 99-107
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2100947872
- Cited by
- 306
- References
- 75
- FWCI
- 11.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.